Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells $136,511.01 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 5,529 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the sale, the insider directly owned 8,752 shares of the company’s stock, valued at $216,086.88. The trade was a 38.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $21.99 on Friday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The company’s 50-day simple moving average is $22.80 and its 200-day simple moving average is $36.75. The stock has a market capitalization of $5.01 billion, a price-to-earnings ratio of 43.13, a PEG ratio of 2.71 and a beta of 2.55.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. During the same period in the previous year, the company earned $0.11 earnings per share. Hims & Hers Health’s quarterly revenue was up 28.4% on a year-over-year basis. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the topic of several research reports. TD Cowen dropped their price target on Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating on the stock in a research report on Tuesday, February 24th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Citigroup raised shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and lifted their price target for the company from $13.25 to $24.00 in a report on Tuesday, March 10th. Bank of America upgraded shares of Hims & Hers Health from an “underperform” rating to a “neutral” rating and increased their price objective for the stock from $12.50 to $23.00 in a research note on Tuesday, March 10th. Finally, Needham & Company LLC raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a report on Monday, March 9th. Three equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $31.29.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently added to or reduced their stakes in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in shares of Hims & Hers Health by 0.8% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock valued at $1,452,000 after acquiring an additional 200 shares during the period. GAMMA Investing LLC increased its holdings in shares of Hims & Hers Health by 6.1% in the 3rd quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock worth $232,000 after acquiring an additional 236 shares during the period. Concurrent Investment Advisors LLC lifted its position in Hims & Hers Health by 1.8% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock valued at $793,000 after purchasing an additional 252 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in Hims & Hers Health by 44.7% in the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after purchasing an additional 283 shares during the last quarter. Finally, W.G. Shaheen & Associates DBA Whitney & Co boosted its stake in Hims & Hers Health by 4.8% during the 3rd quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company’s stock valued at $436,000 after purchasing an additional 350 shares during the period. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.